Treanda bendamustine regulatory update

Cephalon submitted an NDA to FDA for Treanda bendamustine to treat relapsed, rituximab-refractory, indolent B cell non-Hodgkin's lymphoma (NHL). An NDA for Treanda is under priority review by FDA to t...